Global Neurological Biomarkers Market Size is estimated to expand rapidly in coming years, at a CAGR of 13.6 % from 2019 to 2027. In 2017, the global market valuation was USD 5.8 billion, and it is anticipated to be greater than USD xx.xx billion by 2027. The increasing prevalence and attention on early diagnosis and treatment of neurological conditions will drive market growth. A major driver for this demand is the high prevalence of neurological disorders. According to 2018 WHO figures, more than 300 million people worldwide are suffering from clinical depression. In addition, insufficient diagnostics may increase deaths from neurological disorders in both developing and undeveloped countries.

Global Market Growth Opportunities (Revenue, Growth) By 2019-2027

In the brain, spine and nerve there are over 600 forms of neuro-diseases. Even if some specific diseases such as brain stroke, Alzheimer's disease, Parkin's disease, brain tumors, and epilepsy are well studied, it is not uncomplicated or uncommon for most neological disorders to have more profound knowledge of the pathophysiology underlined.

In this sector, aggressive government initiatives and increased neurological diagnostics funding are expected to lead to higher growth. For example, the NINDS, part of the NIH, focuses on increasing the global burden of neurological disorders through legislative policies, testing diagnostic/therapeutic approaches to neurology and developing job opportunities for neuroscience research.

This global market study report analysis offers in-depth insights, revenue details, and other vital information regarding the global neurological biomarkers market, and the various trends, drivers, restraints, opportunities, and threats in the target market till 2025. The report offers insightful and detailed information regarding the various key players operating in the market, their financials, supply chain trends, technological innovations, key developments, apart from future strategies, acquisitions & mergers, and market footprint. The global neurological biomarkers market report has been segmented on the basis of type, application, and region. It includes the estimation of the market size, in terms of value, with respect to 4 main geographies, namely, North America, Europe, APAC, and RoW.

Segment Analysis

By Type Insights: On the basis of type, global neurological biomarkers market has been segmented into genomic, proteomic, metabolomic, imaging, others. Genome biomarkers, powered by growing consumer awareness and technological developments, represented the largest share in 2018. The growth category is also driven by the switch in genetic analysis and genetic advice. Genomic biomarkers are in accordance with human genetic characteristics and predispositions of the patient to guide the future of a neurological practice.

Imaging biomarkers are positioned with the highest growth rate over the projected years, driven by extensive neuroscience R&D and technological advances that allow the visualization of body abnormalities. In addition, in the near future, proteomic and metabolomic biomarkers will be modestly increased.

By End Use Insights: On the basis of end use, global neurological biomarkers market has been segmented into hospital laboratories, independent clinical diagnostic centers, research organizations, others. In 2018, the end-use category was dominated by hospital laboratories. Increased patients inflow of cancer diagnosis in hospitals, increasing consumer awareness and increased health infrastructure investment in developing and underdeveloped countries can contribute to the growth of this segment. Due to increasing funding for research in neuroscience worldwide, the market for research organizations is expected to grow at the highest rate over the forecast period.

Regional Analysis

The neurological biomarkers market is divided into regions that are North America - U.S, Canada, Other; Asia-Pacific -India, Japan, China, Australia, Other; Europe - UK, Russia, France, Brazil, Other; Middle East and Africa. Every region analysis details in sense of growth, revenue, volume, challenges, and opportunities with the regional and global key players. Due to strong commercial success of neurologic diagnostics in the United States, North America accounted for the most important market share in 2018. The rise also involves aggressive government initiatives, increased health spending and the involvement of key producers locally.

Global Neurological Biomarkers Market Size, Share Analysis by Region 2018

The projected growth in Asia Pacific will be the highest during the forecast period. The overall growth rate is likely to be powered by economic development, progress in the health system, increased disposable incomes, and increased consumer awareness. High growth is expected in the neurological biomarker market in the emerging economies such as China, India and South Korea.

As large projects are ongoing in countries like China, India, Australia, and Indonesia in Asia Pacific, the region has potential to bypass any competition. This is also because of the great amount of reserves that the region has. Exploration activities in China are increasing which is why China may have great demand for tin catalysts and compounds. According to the National Bureau of Statistics, neurological biomarkers market will increase the regional demand during the forecast period.

Global Neurological Biomarkers Market Study Objective

To forecast the market size of neurological biomarkers market, along with describing and defining the market, in terms of volume and revenue as well as market opportunities for stakeholders, in order to provide a competitive landscape for global market players.

Market analysis and forecast of neurological biomarkers market on the basis of region, substrate, and application or end-use industry. To profile major market players, and to analyze their market shares and essential competencies comprehensively.

To analyze and elaborate significant factors that will have a major impact on the growth of neurological biomarkers market, such as drivers, restraints, challenges, and opportunities.

The regional analysis of neurological biomarkers market, to induce market size of five global major regions, which include, Europe, North America, South America, Middle East & Africa, and the Asia Pacific.

Strategic analysis of micro markets, in terms of individual prospects, opportunities, growth trends and their involvement in the overall market.

To provide detailed analysis of competitive and strategic developments in the neurological biomarkers market like a new product launch, partnership & agreement, investment & expansion, and company merger & acquisitions.

Key Players Landscape

Abbott, QIAGEN, Myriad RBM, Thermo Fisher Scientific Inc., Athena Diagnostics, Bio-Rad Laboratories, Inc., AbaStar MDx, Inc., Acumen Pharmaceuticals, BANYAN BIOMARKERS, INC., and Alseres Pharmaceuticals, Inc. are some of the key players in the market of neurological biomarkers. In order for companies to become marketplaces, they are undertaking strategic initiatives in both developed and developing countries, such as fusions and acquisitions, new product development and risk capital investments. Industries invest in technological solutions to improve distribution, front end sales and service to customers.

Global Neurological Biomarkers Market Study Report Offer You!

The global neurological biomarkers market study report gives an idea about market size, share, stock, equity, investment and total price analysis. Also, the report provides comprehensively industry insights with all major factors such as market credit, allocation, demand, distribution, market scope, key players, end user & applications, provisions, livestock, commodities and industry economics analysis, future growth & forecast. The global market report includes all depth data like pre-market emphasis, market survey, market investment, industry advice, portfolio, finance, access, trade, market exploration, industry review and market predication & projection to develop effective strategies for optimizing their market position.